

## Index

### a

- ablation therapy 3, 12–27, 299–323
- acoustic impulse and acoustic chemical effects, ultrasound 271–272
- acridine orange 280
- active targeting 9, 13, 49, 74, 84, 137, 140, 142, 152, 198, 199, 201, 252, 255, 300, 363
  - function design of nanoparticles
    - antibody-directed active targeting design 52–53
    - protein and peptide-directed active targeting function design 52
    - small molecule and aptamer-directed active targeting function design 51–52
  - of nanomedicine 364
- Ag NPs 284, 287–288
- agonists 18, 114, 255–257
- AGuIX (activation and guidance of irradiation by X-ray) 352
- alloys materials 335
- Alzheimer's disease (AD) treatment 202, 299, 311
- angiogenic nano-biomaterials
  - delivery vehicles 175
  - intrinsic angiogenic agents 176
- antibacterial nano-biomaterials
  - inorganic 164–165
  - organic 165–166
- antibody-directed active targeting design 52–53
- antibody-drug conjugates (ADCs) 364
- anti-CD19 chimeric antigen receptor (CAR-T 19) 257
- anti-HIV
  - concept of 132–142
  - protease inhibitors 133–141
  - reverse transcriptase inhibitors 133
- anti-SARS-CoV-2 257
- anti-smoking measures 2
- anti-tumor drugs 2
- artificial antibody 13, 252–253
- artificial intelligence (AI)
  - application of 379–380
  - cell replacement therapy for diabetes 380
  - computer vision technology 378
  - deep learning 372
  - definition 371
  - emerging microfluidic technologies 386–389
  - machine learning 372, 378
  - Natural Language Processing (NLP) Technology 378–379
  - precision medicine in cancer treatment 380–382
  - risk assessment models 373
- artificial intelligence generation content (AIGC) 28
- artificial neural network (ANN) 374, 401
- Au@CoFeB nanoparticles 90
- Au@CoFeB-Rg3 nanomedicines 90, 131
- Au-based nanomaterials 350
- Au nanoparticles (AuNPs) 13, 82, 283–284, 287, 289, 352, 358

- auto-targeting design
  - exosomes and supramolecular cell membrane vesicle targeting design 54
  - macrophage targeting function design 53–54
  - platelets targeting function design 53
  - RBC targeting function design 53
- b**
- ball milling 55–56, 131, 335
- bioconjugated QDs 89
- BiOI QDs 356
- bio-safety of nano-biomaterials 182–183
- blood–brain barrier (BBB) 3, 5, 9, 18, 61, 62, 126, 127, 132, 142, 202, 323, 347
- Blumlein pulse generator 304, 305
- c**
- Cabiliv 13
- CA-Gd@C-dots 356
- cancer radiotherapy, milestones in 344–345
- carbon-based nanomaterials 288
- carbon dots (CDs) 285, 288, 356
- carbon nanotubes (CNT) 83, 92, 117, 120, 131, 223, 288, 289
- cavitation effect, ultrasound 270–271
- cefuroxime axetil (CFA) nanoparticles 393
- cell death 10, 11, 255, 257, 282–284, 286, 287, 289, 300, 302, 307, 331, 342, 359
- cell-based drug screening 396
- cell membrane coating nanotechnology
  - electroporation 94
  - extrusion 93
  - graphene nanoplatform-mediated cell membrane coating 94
  - in situ encapsulation with cell-derived vesicles 94
  - sonication 93
- cerebrovascular diseases 1, 2, 5, 6, 301, 302
- chemiluminescence biochemical reaction excitation (CLE) 14, 22
- chimeric antigen receptor (CAR) T cell therapy 248, 257–258
- chronic non-healing wounds 157, 158
- Co/Co<sub>3</sub>O<sub>4</sub> MNPs 236
- coherent scattering 347, 348
- cold tumors 250, 251
- Coley toxin 248
- colloidal gold nanoparticles (GNPs) 83–84
- combination therapy, for cancer treatment 321
- complex cohesive phase separation 144
- Compton effect 347
- computational simulation and machine learning 183
- computer vision technology 378
- condensed phase separation methods 143, 144
- convection-based method 391
- conventional polymer micelles 145
- copper/carbon quantum dot 288
- co-precipitation method 149, 218
- core/shell magnetic nanoparticles 235–237, 240
- coronary artery disease (CAD) 2, 388
- CT nanoprobe 213
  - application of 223–224
- cubic Fe<sub>3</sub>O<sub>4</sub> MNPs 233
- cutaneous wounds
  - definition of 157
  - management of 158
  - nano-biomaterials-based approaches 158, 159
  - nano-biomaterials-based therapeutics, wound healing
    - antibacterial 164–166
    - enabled biophysical regulation 169–175
    - engineering of the wound microenvironment 166–169
    - hemostasis 160–163
  - nano-biomaterials for imaging and monitoring

- wound infection monitoring
    - 177–179
  - wound parameters and markers
    - 179–181
  - nanomaterial-based approaches 158
  - therapeutic and diagnostic
    - management 158
  - CY-PSMA-1-Au<sub>25</sub>NCs radiosensitizer
    - 352–353
  - cytokine interferon- $\alpha$  (IFN- $\alpha$ ) 248
  - cytokines 12, 24, 53, 172, 175, 245–247, 250, 253, 258, 259, 261–263, 332, 381
  - cytotoxicity of Au@CoFe-Rg3 320
- d**
- danger/damage-associated molecular
    - patterns (DAMPs) 282
  - deep brain stimulation (DBS) technology
    - 115, 310, 311
  - deep learning 372, 373, 380, 382, 403
  - dendrimers 74, 131, 138, 139, 272
  - dendritic macromolecules 143, 145, 272
  - diagnostic ultrasound 269
  - Diels–Alder reaction 334
  - DLVO theory 60, 61
  - doxorubicin/paclitaxel (DOX/PTX) 396
  - droplet microfluidics 390
  - drug genomics 374–376
  - drug therapy 114, 117, 132, 153, 299, 300, 385, 392
- e**
- efavirenz 133, 139
  - electric field responsive nanomedicine
    - 312
    - drug loading 312
    - efficacy 312
    - surface modification 312
    - synthesis process 312
  - emulsification method 116, 143, 312, 390
  - emulsion polymerization 133, 143
  - engineering of the wound
    - microenvironment
      - MMPs 167–169
      - pro-inflammatory mediators 169
      - redox modulation 167
  - enhanced permeability and retention
    - (EPR) effect 4, 49, 73, 74, 199, 250, 272, 280, 352
  - epibromohydrin functionalized
    - TiO<sub>2</sub>@ $\gamma$ -Fe<sub>2</sub>O<sub>3</sub> nanoparticles 240
  - epithelial barrier 52, 137
  - exchange coupling interaction 235–237, 239
  - external beam radiotherapy (EBRT) 342, 346, 362
- f**
- facile freeze-annealing process 27
  - FA-LNPs 52
  - Fenton nanoparticles 284
  - Fe<sub>3-x</sub>O<sub>4</sub>/CoFe<sub>2</sub>O<sub>4</sub> core–shell MNPs 235
  - Fe<sub>3</sub>O<sub>4</sub> nanoparticles 149, 211, 227, 262, 333, 334, 336
  - Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>@PNG-Hy MNPs 239, 240
  - ferrite materials 334–335
  - focused ultrasound (FUS) 14, 269, 275, 280
  - frequently-used natural polymers 393
- g**
- gadolinium chelates coated gold
    - nanoparticles Au@DTDTPA-Gd<sub>50</sub> 352
  - Gd-based theranostic nano-agent 352
  - gene-based therapies 197
  - genomics of nanomedicine
    - definition 375
    - genomic responses 377
    - modifications 376
    - pharmacokinetic characteristics 375
    - toxicity 376–377
  - genomics, definition 372
  - gold-levonorgestrel nanoclusters
    - (Au<sub>8</sub>NCs) 350
    - structure and size characterization 351

- gold nanoclusters (AuNCs) 350
- gold nanoparticles for bioimaging 54
- gold-nanoparticles-reduced graphene oxide (NAu-rGO) nanocomposite 289
- gold nanorods (GNRs) 54, 94, 287, 288, 346, 350
- gold nanoshells 287
- Goldbody 13
- graphene nanopatform-mediated cell membrane coating 94
- graphene oxide (GO) 85, 119, 120, 165, 288–289
- graphene, synthesis and application of 85–86
- h**
- hard magnetic nanoparticles 229, 230
- hard/soft (CoFe<sub>2</sub>O<sub>4</sub>/Fe<sub>3</sub>O<sub>4</sub>) nanocomposites 238
- hematoporphyrin 279, 280
- heterogeneous MNPs 229, 230
- high-intensity focused ultrasound (HIFU) 8, 14, 18, 23, 28, 269, 270, 273
- highly fluorescent QDs 88
- high-pressure steep pulse third-generation machine 308
- high-throughput drug screening based on cell assays 396–398 organ-on-a-chip 398–400
- high-Z-element-based drugs 347
- high-Z-metal-based nanomaterials physical and biochemical radio-sensitization mechanism of 349 physicochemical and biochemical radio-sensitization mechanism of 349
- hot tumors 250, 251
- hydrodynamic flow focusing (HFF) devices 394
- hydrophilic polymers 79, 81
- hydrophobic QDs 88
- hydrothermal synthesis method 149, 219
- hyperbaric oxygen therapy (HBO) 158
- hyperthermia 22, 54, 83, 86, 94, 227, 228, 329 magnetic hyperthermia 227, 228, 236, 238–239, 329–332, 334–339 tumor hyperthermia method 329
- hypoxia-inducible factor (HIF) 175, 176, 293
- i**
- <sup>131</sup>I-based RIT 359
- immune agonist 12
- immune checkpoints 248, 250
- immune system and immune response 245–247
- indoleamine 2,3-dioxygenase (IDO) 248
- inorganic antibacterial nano-biomaterials 164–165
- inorganic-based nanomedicines 146, 148 magnetic material 120–121 nano-mesoporous silicon 122 nanocalcium 122 nanocarbon 120 nanogold 119–120 quantum dots (QDs) 117–118
- inorganic nanoparticles 395 colloidal gold nanoparticles (GNPs) 83–84 graphene 85–86 layered double hydroxides (LDHs) 89 magnetic nanoparticles (MNPs) 86–88 mesoporous silica nanoparticles (MSNPs) 84–85 multifunctional composite nanoparticles 90 quantum dots (QDs) 88–89
- Instance 1 337
- Instance 2 337–338
- Instance 3 338–339
- intelligent nanomedicine 6, 358
- interleukin-2 (IL-2) 248
- internal radioisotope therapy (RIT) 343, 358 advantages 358 alpha (α) particle emitters 359, 360

- Auger particle emitters 360, 362
- beta ( $\beta$ ) particle emitters 359, 361
- drawbacks 358
- intracellular magnetic hyperthermia
  - therapy 332
- intractable diseases 1–3, 6, 10, 14, 23, 27, 28, 49, 263, 302, 323
- intrinsic angiogenic agents 176
- ionizing radiation 341
  - response of normal cells to 342–343
- k**
- knee osteoarthritis (KOA) 338, 339
- l**
- lab on a chip (LOC) 386
- $\text{La}_{1-x}\text{Sr}_x\text{MnO}_3$  (LSMO) 336, 337
- layered double hydroxides (LDHs) 89
- linear energy transfer (LET) 342, 359, 360
- lipid nanoparticles (LNPs) 52, 113, 131, 140, 200–202, 393–395
- liposomal doxorubicin (Doxil) nanodrugs 9
- liposomal nanoparticles
  - in drug delivery 77–78
  - extrusion technique 76
  - heating method 77
  - microfluidization 76
  - sonication 76
- liposomes 138, 394
  - nanocarrier preparation 394–395
  - preparation methods 138
- liquid antisolvent precipitation (LASP)
  - method 392
- low-intensity focused ultrasound (LIPUS) 269, 270
- m**
- machine learning 28, 182, 183, 372, 373, 378, 380–382, 400–403
- macrophage targeting function design 53–54
- macroscopic dose enhancement factors (MDEF) 350
- magnetic field responsive nanomedicine
  - synthesis
  - alloys materials 335
  - composite materials 335–336
  - $\text{Fe}_3\text{O}_4$  materials 333–334
  - ferrite materials 334–335
  - other materials 336–337
- magnetic heat therapy apparatus 330
- magnetic hyperthermia 227, 228, 236, 238–239, 329–332, 334–339
  - on tumor cells 331–332
- magnetic mediated hyperthermia (MMH)
  - applications
    - Instance 1 337
    - Instance 2 337–338
    - Instance 3 338–339
  - cytotoxicity 332–333
  - killing effect 331–332
  - magnetic field responsive
    - nanomedicine synthesis
    - alloys materials 335
    - composite materials 335–336
    - $\text{Fe}_3\text{O}_4$  materials 333–334
    - ferrite materials 334–335
    - other materials 336–337
  - magnetic hyperthermia on tumor cells 331–332
  - magneto-thermal conversion
    - mechanism 330–331
  - overview 329–330
  - thermal effects 329
- magnetic nano-biomaterials 210, 212
- magnetic nanoparticles (MNPs) 86
  - biomedical applications
    - magnetic hyperthermia 238–239
    - magnetic resonance imaging (MRI) 236–237
    - neuromodulation 240–242
    - targeted drug delivery 239–240
  - in biomedical science 228
  - exchange coupling interaction 235–236
  - hard magnetic nanoparticles 230
  - magnetic moment structure of 228–229

- magnetic nanoparticles (MNPs) (*contd.*)
  - schematic representation 230
  - soft magnetic nanoparticles 228–229
- magnetic nanoprobe
  - application of 222–223
  - co-precipitation method 218–219
  - hydrothermal synthesis method 219
  - thermal decomposition method 219
- magnetic regulation
  - composition 233–234
  - shape 232–233
  - size 230–232
- magnetic resonance imaging (MRI) 22,  
87, 88, 90, 94, 120, 212, 214, 222,  
224, 227, 236–237, 242, 275, 313,  
318–320, 333, 334, 344, 351–353,  
356, 364, 378, 386
- magnetolectric nanoparticles (MENPs)  
241, 242
- magnetoplasma nanocore–shell structure  
208
- magneto-thermal conversion mechanism  
330–331
- mechanical effects, ultrasound 270
- mechanism of nanomedicine enhancing  
immunotherapy 248–252
- mechanism of tumor immunotherapy  
247–248
- MedPulser® system 307
- mesoporous silica nanoparticles (MSNPs)  
84–85
- metallic-based nanomedicines 122–125,  
148–150
- metal nanoclusters (NCs) 284
- metal-organic frameworks (MOFs)
  - preparation and characterization of  
123
  - tumor therapy 123–125
- methylene blue (MB) 280
- methyl methacrylate (MMA) 336
- micelle 9, 22, 51, 55, 114, 131, 138–140,  
143–146, 148, 150, 217, 272, 300,  
301, 391
- microfluidic chips fabrication 387–389
- microfluidic concentration gradient  
generators 390, 391
- microfluidic synthesis 56–58, 395
- microfluidic systems 387, 395, 401, 403
- microfluidic technology 386
  - AI assisted nanomedicine 400–402
  - high-throughput drug screening  
396–400
    - based on cell assays 396–398
    - organ-on-a-chip 398–400
  - medicine development 386–391
  - microfluidic chips fabrication  
387–389
  - microfluidic units 390–391
  - nanomedicines 391–396
    - drug nanoparticles preparation  
392–393
    - nanocarrier preparation 393–396
- micro total analysis system ( $\mu$ TAS) 386
- mixture (hybrid) nanoparticles 90–92
- molecular imaging probe 208, 219, 224
- monoclonal antibody ipilimumab 248
- monodisperse  $\text{Fe}_3\text{O}_4$  nanoparticles 227
- mononuclear phagocytosis system (MPS)  
50, 62
- multi-drug resistant (MDR) 11, 12, 164,  
166
- multifunctional composite nanoparticles  
90
- multifunctional integrated theranostic  
nanoparticle platforms design  
363
- multifunctional/multimodal nanoprobe  
214
- multi-functional (target) nanomedicines  
150–152
- multimodal iron-based nanodrug  
(Au@CoFe-Rg3)
  - design and synthesis 313–315
  - in situ anticancer effects, in liver cancer  
320–321
  - physical imaging applications  
318–320
  - physical properties and structural  
analysis 315–318

- multi-modal theranostics instruments
  - 27
- multi-mode nanomedicines 6, 14, 18, 24, 25, 27, 28
- n**
- nano-biomaterials, cutaneous wound
  - assessment and therapy 158
- nano-biomaterials-enabled biophysical
  - regulation of wound healing
    - angiogenic nano-biomaterials 175
    - bio-electrical stimulation 173–175
    - mechanical cues 171–173
    - surface nanotopographical features
      - 171
- nanocalcium 117, 122
- nanocarbon 117, 120
- nanocarriers, characteristics 73
- nanocrystals (NCs) 55, 90, 149, 161, 167, 209, 290, 292, 354, 395
- nano-dosage forms or nano-carriers 138
- nano drug carriers 141, 251
- nanodrug mediated PEF combined
  - therapy 322
- bacterial infection treatment 323
- cancer treatment 322–323
- enhancing therapeutic effects 303
- instruments and parameters
  - capacitor discharge device 305
  - electrode system 305
  - pulse generator 304–305
  - pulse parameter adjustment
    - 305–306
  - pulse power amplifier 305
- neurological disease treatment 323
- overcoming drug resistance 303
- personalized treatment 303
- reduced side effects 303
- nanoemulsion 6, 52, 138, 140, 141, 152
- nanoenzymes 7, 11, 24, 27
- nanogold 117, 119–120
- nano-immunotherapy 24
- nanoknife system 307, 308
- nanomaterial-based PSs
  - Ag NPs 284
  - AuNPs 283–284
  - carbon-based nanomaterials 288–289
  - carbon dots (CDs) 285
  - metal nanoclusters (NCs) 284–285
  - noble metal-based nanomaterials 286
  - photothermal agent 286
  - photothermal therapy 286
  - semiconductor-based nanomaterials
    - 289
  - transition metal carbides (TMCs) 285
- nanomaterials
  - ball milling 55–56
  - biological methods 58–59
  - manufacturing issues 96
  - microfluidic synthesis 56–58
  - nanoprecipitation 56
  - personalized protein nanoparticles (PNP) 58
  - physico-chemical characterization
    - of 95
  - regulatory issues 95–96
  - safety concerns 95
- nanomedicine(s)
  - active targeting function design of
    - nanoparticles 51–53
  - application examples 275–276
  - artificial intelligence 377–379
  - auto-targeting design
    - exosomes and supramolecular cell
      - membrane vesicle targeting
        - design 54
    - macrophage targeting function
      - design 53–54
    - platelets targeting function design
      - 53
    - RBC targeting function design 53
  - concept of 272
  - future development of 27–28
  - genomics of 374–377
  - historical timeline of major
    - developments of 6–7
  - interdisciplinary features of 12–27
  - in vitro or in vivo 3D traceable function
    - gold nanoparticles for
      - bioimaging 54

- nanomedicine(s) (*contd.*)
  - quantum dots for Bioimaging 54–56
  - key features of 4–6
  - microfluidic technology 391–396
  - nanotechnology translational 6–12
  - passive targeting function design 49, 51
  - surface modification
    - charged materials 60–62
    - conformation change 62–63
    - multi-ligand modified
      - nano-preparations 66
    - single targeting ligand 63–65
    - steric resistance 62
  - targeting delivery of gene
    - based nanomedicines to the brain 202
    - based nanomedicines to the liver 200, 201
    - based nanomedicines to the lung 200–202
    - based nanovaccines to the LNs 200
    - based nanovaccines to the spleen 199–200
  - therapies to the tumors 198–199
  - therapy theory of 272–273
  - ultrasonic atomization pyrolysis 274
  - ultrasonic chemical precipitation 274
  - ultrasonic electrochemical technology 274–275
  - ultrasonic reduction 275
- nanomedicine mediated immunotherapy
  - immunological applications
    - agonists 255–257
    - artificial antibody 252–253
    - cytokines 261–263
    - nanomedicines combined CAR-T therapy 257–258
    - nanovaccines 258–261
    - reprogrammed immunity 253–255
  - mechanism of nanomedicine
    - enhancing immunotherapy 248–252
  - mechanism of tumor immunotherapy 247–248
  - nanomedicine mediated pulsed electric field (PEF) therapy 24, 299–323
    - advantages 302
  - nanomedicine mediated ultrasound
    - therapy, equipment for 273–274
  - nanomedicine mediating immunotherapy
    - immune system and immune response 245–247
  - nanomedicines combined CAR-T therapy 257–258
  - nanomedicines for nervous system
    - diseases
      - concepts and types of 113–114
    - inorganic-based nanomedicines
      - magnetic material 120–121
      - nanocalcium 122
      - nanocarbon 120
      - nanogold 119–120
      - nano-mesoporous silicon 122
      - quantum dots (QDs) 117–118
    - metallic-based nanomedicines 122–125
    - multi-functional nanomedicines for 125–128
      - chemotherapy 125–126
      - combination treatment strategy 127
      - perspectives of 127–128
    - polymer-based nanomedicine
      - emulsification method 116
      - reductive reaction reduction method 116
      - solvent evaporation method 116
    - polymer-based nanomedicine typical application
      - inclusion of nanomaterials 117
      - targeted drug delivery 116–117
      - tissue repair and regenerative medicine 117
      - vaccines and immunotherapy 117
    - therapeutic methods for 114–116
  - nanomedicines, microfluidic technology
    - drug nanoparticles preparation 392–393
    - nanocarrier preparation 393–396



- nanomedicine synthesis with  
 radio/nuclear radiation response  
 362–364
- nano-mesoporous silicon 117, 122
- nanoparticle carriers 135, 312
- nanoprecipitation 56, 80, 81, 131, 143,  
 144, 392–394
- nanoprobes  
 CT imaging 213  
 magnetic 210–212  
 multifunctional/multimodal 214  
 nuclide imaging 213–214  
 optical nanoprobe 208–210  
 photoacoustic imaging 212–213  
 synthesis methods  
 magnetic nanoprobe 218–219  
 noble metal 216–218
- nanoprobes for wound infection  
 monitoring 177
- nanoscale coordination polymers (NCP)  
 11, 12
- nanosecond pulsed electric fields  
 (nsPEFs) 300  
 tumor treatment 300
- nanosecond pulse tumor ablation system  
 308, 309
- nanospheres 54, 114, 119, 131, 138, 139,  
 141, 152, 283, 287
- nanotechnology 371  
 mediated radiation therapy 346  
 translational nanomedicine 6–12
- nanotheranostics 6, 10, 14, 24
- nanotherapeutics 6, 49
- nanovaccines 7, 199–200, 257–261
- Natural Language Processing (NLP)  
 Technology 378–379
- needle shaped electrode 305
- neuromodulation 227, 228, 236, 240–242
- noble metal-based nanomaterials  
 286–288
- noble metal nanoprobes  
 chemical synthesis method 216–218  
 electrochemical process 218  
 photochemical method 217  
 template-based method 217–218
- non-porphyrinoid-based PSs 280
- non-specific immune response 245
- non-viral vectors 197
- NP albumin-bound paclitaxel 9
- nucleolin-targeted AS1411  
 aptamer 240
- nuclide imaging nanoprobe 208,  
 213–214
- O**
- oil-in-water (O/W) emulsion 140
- optical nanoprobe 208–210, 219–222
- organic antibacterial nano-biomaterials  
 164–166
- organic polymer chips 388
- organ-on-a-chip 390, 391, 398–400, 403
- overhealing 157, 180
- P**
- parallel electrode 305
- Parkinson's disease 13, 114–116, 242,  
 299, 310, 311, 323
- passive targeting 49–51, 54, 135, 137,  
 142, 151, 152, 198–199, 220, 223,  
 252, 255, 280
- passive targeting function design  
 shape dependent biological effect of  
 nanoparticles 50–51  
 size dependent biological functions 50  
 surface charge and PEGylation of  
 nanoparticles 50
- pathogen-associated molecular patterns  
 (PAMPs) 246
- PEGylated FePt–Fe<sub>2</sub>O<sub>3</sub> core-shell  
 nanoparticles 240
- personalized protein nanoparticles (PNP)  
 58
- phagocytosis 6, 50, 62, 66, 113, 135–137,  
 140, 152, 223, 261
- photoacoustic imaging nanoprobe 208,  
 212–213, 222–223  
 application of 222–224
- photodynamic and photothermal  
 synergistic therapy 291–292

- photodynamic therapy (PDT) 3, 14, 18,  
 22, 54, 123–125, 128, 153, 164, 220,  
 259, 279–293, 322, 323, 346
- photosensitizers (PSs)/photothermal  
 agent 279
- photoshock ablation 22
- photothermal ablation (PTA) 22
- photothermal agent 176, 279, 280, 286,  
 289, 290, 292, 293
- photothermal therapy 286
- photothermal treatment (PTT) 94, 164,  
 165, 177, 178, 279–286, 288–293,  
 364
- physical sensitization mechanism 349
- pilot microfluidic process 27
- plant mediated green synthesis of  
 nanoparticles 59
- platelets targeting function design 53
- PLGA<sub>SS</sub>-D@BPQDs nanosystem  
 356–358
- polydimethylsiloxane (PDMS) 92, 171,  
 172, 387, 388, 399, 400
- polydispersity index (PDI) 393, 394
- poly (ethylene glycol)-poly  
 (lactide-co-glycolic acid)  
 (PEG-PLGA) 56
- poly(lactic-co-glycolic acid) (PLGA) 52,  
 80, 82, 93, 139, 141, 143, 253, 356,  
 357, 394, 401
- polymerase chain reaction (PCR) 170,  
 172, 388
- polymer-based nanomedicines 116–117,  
 142–146
  - emulsification method 116
  - reductive reaction reduction method  
 116
  - solvent evaporation method 116
- polymer-based nanomedicine typical  
 application
  - inclusion of nanomaterials 117
  - targeted drug delivery 116–117
  - tissue repair and regenerative medicine  
 117
  - vaccines and immunotherapy 117
- polymeric micelle paclitaxel 9
- polymeric nanoparticles (NPs) 74,  
 78–82, 133, 393
  - controlled drug release 73
  - hydrophilic polymers 81
  - nanoprecipitation/solvent  
 displacement method 80
  - polymerization methods 81
  - salting out method 79–80
  - solvent evaporation method 79
  - spontaneous emulsification/solvent  
 diffusion method 79
- polymerization method 81, 143, 336
- polymer micelles 143, 145, 146, 272, 300,  
 301, 391
- polymer nanocarriers, characteristics of  
 141–145
- polymethacrylic acid (PMMA) 336, 387,  
 398
- polyvinylpyrrolidone (PVP) 62, 80, 289,  
 313, 394
- porphyrinoid-based PSs 280
- pPD-Gd@C-dots 356
- precision medicine in cancer treatment  
 380–382
- protein and peptide-directed active  
 targeting function design 52
- pulse count 306
- pulsed laser photogenesis 22
- pulse frequency 305, 306
- pulse voltage 305, 306
- pulse waveform generators, advantages  
 and disadvantages of 305, 306
- pulse width 305–307
- q**
- quantitative structure–toxicity  
 relationship (QSTR) 401
- quantum dots (QDs) 88, 117, 353, 395
  - for Bioimaging 54–55
  - copper/carbon 288
  - inorganic-based nanomedicines  
 117–118
- quantum drugs 24

**r**

- radiation sensitizers 347
- radiation therapy/radiotherapy (RT)
  - for cancer treatment 341–364
  - side effects 344
- radio-enhancers 347
- radio/nuclear radiation therapy,
  - nanomedicine mediated 341–364
- radiosensitizers 347–358
  - for radiation therapy 347–358
- Raman nanoprobe 209
- RBC targeting function design 53
- RD<sup>®</sup> steep nanosecond pulse generator 309
- redox modulation of the wound
  - microenvironment 167
- reductive reaction reduction method 116
- reprogrammed immunity 253–255
- Rg3-sheltered dynamic nanocatalysts 91–92
- rose Bengal (RB) 280

**s**

- selective organ targeting (SORT) strategies 200, 201
- self-assembled core-shell nanoscale
  - coordination polymer (NCP) nanoparticles 11, 12
- semiconductor-based nanomaterials 289
  - copper sulfide (CuS) 290
  - molybdenum disulfide 290
  - WS<sub>2</sub> 290
- semiconductor QDs, as photo-and
  - radio-sensitizers 356
- siliceous materials 387
- single or multi walled carbon nanotube (SWCNT/MWCNT) 289
- size-dependent magnetic moments 231
- small molecule and aptamer-directed
  - active targeting function design 51–52
- smart nanomedicine 6, 10, 24, 27, 28
- sodium iodide transporter (NIS) 359

- soft/hard (Fe<sub>3</sub>O<sub>4</sub>/CoFe<sub>2</sub>O<sub>4</sub>)
  - nanocomposites 238
- soft magnetic nanoparticles 229
- solid lipid nanoparticles (SLN) 113, 131, 140
- solid-phase sintering and
  - vapor–liquid–solid growth (SS–VLS-like) method 27
- solvent evaporation method 79, 116
- sonochemical dynamics (SDT) 14, 18
- specific immune response 245, 259
- spray drying method 143, 145, 393
- standardized preparation protocols 182
- stealth effect 140
- stimuli-responsive drug delivery 51
- superatom cluster drugs 24
- superparamagnetic iron oxide
  - nanoparticles (SPIONs) 222, 338, 382
- supervised learning 372, 373
- synergistic anticancer research 312–321
- synthetic polymer nanocarriers 394

**t**

- targeted drug delivery 64, 78, 113, 116–117, 140, 151, 152, 199, 227, 228, 239–240, 300
- targeted drug delivery system (TDDS) 78, 140, 151, 152
- targeted siRNA polymeric NPs (CALAA-01) 9
- targeting delivery of gene based
  - nanomedicines to the brain 202
- targeting delivery of gene-based
  - nanomedicines to the liver 200, 201
- targeting delivery of gene based
  - nanomedicines to the lung 200–202
- targeting delivery of gene based
  - nanovaccines to the LNs 200
- targeting delivery of gene based
  - nanovaccines to the spleen 199–200

- targeting delivery of gene therapies to the tumors 198–199
  - targeting the pro-inflammatory mediators 169
  - telmisartan (TEL) 393
  - theranostic nano-biomaterials for wound infection control 177–179
  - theranostic nano-platforms 363
  - therapeutic  $\alpha$ -emitters 359–360
  - therapeutic  $\beta$ -emitters 359, 361
  - therapeutic Auger-emitters 362
  - thermal decomposition method 219, 235
  - thermal effect, ultrasound 270
  - thixotropic effect, ultrasound 271
  - tissue Repair and Regenerative Medicine 117
  - Toll-like receptor 9 (TLR9) pathways 401
  - transient receptor potential vanilloid 4 (TRPV4) 241
  - transition metal based nanomedicines 11
  - transition metal carbides (TMCs) 285
  - transition-metalloptosis 11
  - tricarboxylic acid (TCA) cycle 10
  - tumor hyperthermia method 329
  - tumor immune editing hypothesis 254
  - tumor immune editing process 255
  - tumor immune monitoring hypothesis 253, 254
  - tumor immune stimulation hypothesis 254
  - tumor infiltrating lymphocytes (TILs) 250, 402
  - tumor treatment
    - nanomedicine advantages 302
    - nanosecond pulsed electric fields (nsPEFs) 300
  - two-pore domain potassium channels (TREK-1) 241
  - type 1 diabetes (T1D) 380
- U**
- ultrasmall Au<sub>25</sub> nanoclusters (NCs) for selective prostate cancer targeting 352
  - ultrasonic atomization coupling pyrolysis process 27
  - ultrasonic atomization pyrolysis 274
  - ultrasonic chemical precipitation 274
  - ultrasonic electrochemical technology 274
  - ultrasonic reduction 275
  - ultrasound therapy and therapy theory 269–270
  - ultrathin Ti<sub>3</sub>C<sub>2</sub> MXene nanosheets 292
  - underhealing 157
  - unsupervised learning 372
- V**
- vaccines and immunotherapy 117
  - vascular cell adhesion molecule-1 (VCAM-1) 52
  - vibrating sample magnetometer (VSM) method 335, 336
  - viral vectors 197, 257
  - VivaGel™ 139
- W**
- water-in-oil (W/O) 140, 141, 150
  - water-insoluble organic solvents 144
  - wound infection monitoring
    - nanoprobes for 177
    - theranostic nano-biomaterials 177–179
  - wound parameters and markers
    - physiological and pathological 179–180
    - stem cell-based wound therapy 180
    - wound scarring markers 180–181
- X**
- X-rays interaction with high-Z materials 348













